Indaptus Therapeutics, Inc. (INDP)

NASDAQ: INDP · Real-Time Price · USD
1.000
-0.040 (-3.85%)
Nov 22, 2024, 4:00 PM EST - Market closed
-3.85%
Market Cap 10.20M
Revenue (ttm) n/a
Net Income (ttm) -14.89M
Shares Out 10.20M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 102,376
Open 1.040
Previous Close 1.040
Day's Range 0.840 - 1.040
52-Week Range 0.840 - 3.100
Beta 1.13
Analysts Strong Buy
Price Target 8.50 (+750.0%)
Earnings Date Nov 12, 2024

About INDP

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 7
Stock Exchange NASDAQ
Ticker Symbol INDP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for INDP stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 750.00% from the latest price.

Price Target
$8.5
(750.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infectio...

18 hours ago - GlobeNewsWire

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or tar...

11 days ago - GlobeNewsWire

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...

15 days ago - GlobeNewsWire

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferenc...

4 weeks ago - GlobeNewsWire

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present post...

7 months ago - GlobeNewsWire

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Di...

8 months ago - GlobeNewsWire

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses

8 months ago - GlobeNewsWire

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended Dec...

9 months ago - GlobeNewsWire

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort

9 months ago - GlobeNewsWire

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments,...

10 months ago - GlobeNewsWire

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza Patent will provide additional protection covering a compositi...

11 months ago - GlobeNewsWire

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 an...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Poster to be presented at 38 th Annual Meeting of the Society for Immunotherapy of Cancer on November 4 , 2023

1 year ago - GlobeNewsWire

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler will present at Tribe Public's Webinar Presentation and Q&A Event ...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. ...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and pr...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced completion of the first cohort of patients who received a single do...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announce...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment...

1 year ago - GlobeNewsWire

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today ann...

1 year ago - GlobeNewsWire

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Dr. Newman also to give two presentations on the Company's Decoy platform at the event to be held in Boston May 9-11, 2023 Dr. Newman also to give two presentations on the Company's Decoy platform at ...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today a...

1 year ago - GlobeNewsWire

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present at the Investor Summit Conference

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today a...

1 year ago - GlobeNewsWire